Published in Nat Genet on February 01, 2009
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem (2009) 3.29
Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol (2011) 2.70
Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein. Neuron (2014) 2.69
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (2013) 2.61
Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci (2010) 2.29
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A (2012) 2.16
Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J (2010) 2.12
A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol (2011) 1.95
Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A (2011) 1.85
Role of manganese in neurodegenerative diseases. J Trace Elem Med Biol (2011) 1.73
Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet (2013) 1.63
An intrinsically disordered yeast prion arrests the cell cycle by sequestering a spindle pole body component. J Cell Biol (2012) 1.60
RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion (2011) 1.40
Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. Dis Model Mech (2010) 1.33
Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J Neurosci (2012) 1.32
Lysosomal impairment in Parkinson's disease. Mov Disord (2013) 1.27
Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A (2013) 1.24
Extracellular dopamine potentiates mn-induced oxidative stress, lifespan reduction, and dopaminergic neurodegeneration in a BLI-3-dependent manner in Caenorhabditis elegans. PLoS Genet (2010) 1.23
Cd2+, Mn2+, Ni2+ and Se2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2. Biochem Biophys Res Commun (2009) 1.21
Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. J Biol Chem (2011) 1.19
Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol (2009) 1.19
Neurological impacts from inhalation of pollutants and the nose-brain connection. Neurotoxicology (2011) 1.19
Neuronal ceroid lipofuscinosis: impact of recent genetic advances and expansion of the clinicopathologic spectrum. Curr Neurol Neurosci Rep (2013) 1.18
Manganese-induced trafficking and turnover of the cis-Golgi glycoprotein GPP130. Mol Biol Cell (2010) 1.16
Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity. Hum Mol Genet (2012) 1.15
PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum Mol Genet (2011) 1.11
Profilin 1 associates with stress granules and ALS-linked mutations alter stress granule dynamics. J Neurosci (2014) 1.09
Mechanisms of lead and manganese neurotoxicity. Toxicol Res (Camb) (2013) 1.09
The divalent metal transporter homologues SMF-1/2 mediate dopamine neuron sensitivity in caenorhabditis elegans models of manganism and parkinson disease. J Biol Chem (2009) 1.07
Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction. J Neurochem (2010) 1.07
Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics (2010) 1.06
Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem (2009) 1.06
Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener (2009) 1.05
Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem (2011) 1.04
A one base pair deletion in the canine ATP13A2 gene causes exon skipping and late-onset neuronal ceroid lipofuscinosis in the Tibetan terrier. PLoS Genet (2011) 1.02
ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese. Neurotoxicology (2012) 1.02
Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum Mol Genet (2014) 1.01
Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms. EMBO Mol Med (2009) 1.00
Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Mol Neurodegener (2010) 1.00
Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury. Neurochem Int (2012) 0.99
Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Hum Mol Genet (2011) 0.99
Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Hum Mol Genet (2013) 0.99
Cellular function and pathological role of ATP13A2 and related P-type transport ATPases in Parkinson's disease and other neurological disorders. Front Mol Neurosci (2014) 0.98
Manganese homeostasis in Saccharomyces cerevisiae. Chem Rev (2009) 0.98
Manganese homeostasis in the nervous system. J Neurochem (2015) 0.98
Review: Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. Neuropathol Appl Neurobiol (2015) 0.96
Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet (2014) 0.96
Engineering enhanced protein disaggregases for neurodegenerative disease. Prion (2015) 0.96
Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum Mol Genet (2013) 0.96
The endoplasmic reticulum (ER)-associated degradation system regulates aggregation and degradation of mutant neuroserpin. J Biol Chem (2011) 0.95
The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet (2014) 0.95
Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J Mol Neurosci (2011) 0.95
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. J Neurochem (2012) 0.94
Metal imaging in neurodegenerative diseases. Metallomics (2012) 0.93
The role of the Parkinson's disease gene PARK9 in essential cellular pathways and the manganese homeostasis network in yeast. PLoS One (2012) 0.93
Mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis (2011) 0.93
Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS One (2014) 0.92
Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease. Front Neurosci (2016) 0.91
A lipid switch unlocks Parkinson's disease-associated ATP13A2. Proc Natl Acad Sci U S A (2015) 0.91
TDP-43 toxicity in yeast. Methods (2010) 0.91
α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. Proc Natl Acad Sci U S A (2012) 0.91
Altered manganese homeostasis and manganese toxicity in a Huntington's disease striatal cell model are not explained by defects in the iron transport system. Toxicol Sci (2010) 0.91
Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum Mol Genet (2011) 0.91
Manganese exposure induces α-synuclein aggregation in the frontal cortex of non-human primates. Toxicol Lett (2012) 0.91
Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem (2016) 0.91
Genetic factors and manganese-induced neurotoxicity. Front Genet (2014) 0.90
Manganese neurotoxicity and the role of reactive oxygen species. Free Radic Biol Med (2013) 0.90
Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. J Neurosci Res (2012) 0.89
Metal-induced neurodegeneration in C. elegans. Front Aging Neurosci (2013) 0.89
Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C. elegans Parkinson's model. Cell Death Dis (2014) 0.89
Mitochondrial Dysfunction in Parkinson's Disease. Exp Neurobiol (2015) 0.88
Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism. PLoS One (2012) 0.88
ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein. J Neurosci (2014) 0.88
Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Front Aging Neurosci (2010) 0.88
Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). PLoS One (2011) 0.88
Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism-dystonia. Nat Commun (2016) 0.88
Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms. BMC Genomics (2012) 0.87
The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models. Cell Death Differ (2012) 0.87
"Manganese-induced neurotoxicity: a review of its behavioral consequences and neuroprotective strategies". BMC Pharmacol Toxicol (2016) 0.86
Manganese accumulates within golgi apparatus in dopaminergic cells as revealed by synchrotron X-ray fluorescence nanoimaging. ACS Chem Neurosci (2009) 0.86
A yeast model for polyalanine-expansion aggregation and toxicity. Mol Biol Cell (2011) 0.86
Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans. PLoS One (2010) 0.86
Watching worms whither: modeling neurodegeneration in C. elegans. Prog Mol Biol Transl Sci (2011) 0.86
Mitochondrion-mediated cell death: dissecting yeast apoptosis for a better understanding of neurodegeneration. Front Oncol (2012) 0.85
Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. J Neurosci (2016) 0.85
Proteins in aggregates functionally impact multiple neurodegenerative disease models by forming proteasome-blocking complexes. Aging Cell (2014) 0.85
Glucocerebrosidase involvement in Parkinson disease and other synucleinopathies. Front Neurol (2012) 0.85
Manganese efflux in Parkinsonism: insights from newly characterized SLC30A10 mutations. Biochem Biophys Res Commun (2013) 0.85
Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol (2014) 0.85
The mitochondrial kinase PINK1, stress response and Parkinson's disease. J Bioenerg Biomembr (2009) 0.84
A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders. Neurotherapeutics (2012) 0.84
Shadows of an absent partner: ATP hydrolysis and phosphoenzyme turnover of the Spf1 (sensitivity to Pichia farinosa killer toxin) P5-ATPase. J Biol Chem (2012) 0.83
ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun (2013) 0.83
The yeast p5 type ATPase, spf1, regulates manganese transport into the endoplasmic reticulum. PLoS One (2013) 0.83
The genetics of Caenorhabditis elegans. Genetics (1974) 102.14
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature (2006) 11.91
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature (2006) 11.81
Genome-wide RNAi screening in Caenorhabditis elegans. Methods (2003) 7.83
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry (1996) 6.47
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A (2006) 5.78
A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature (2004) 5.57
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science (2003) 4.45
Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol (2001) 4.27
Evolution of substrate specificities in the P-type ATPase superfamily. J Mol Evol (1998) 4.14
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet (2006) 4.01
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci (2006) 3.37
Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A (1995) 3.36
A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast (2007) 3.30
Biology, structure and mechanism of P-type ATPases. Nat Rev Mol Cell Biol (2004) 3.00
alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A (2002) 2.81
Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron (2006) 2.66
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64
Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2000) 2.63
Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry (2003) 2.54
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology (2007) 2.51
Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci (2005) 2.50
DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem (2005) 2.24
Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem (2002) 2.19
TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem (2002) 1.77
A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem (2005) 1.60
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am J Pathol (2007) 1.52
Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell (2008) 1.48
Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet (2003) 1.36
Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J Neurochem (2008) 1.27
DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS One (2008) 1.18
Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? Neurosignals (2007) 1.14
DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein. J Neurochem (2005) 1.08
A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol (2001) 1.00
Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology (2007) 0.92
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
Hsp90 as a capacitor of phenotypic variation. Nature (2002) 8.90
Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell (2007) 8.84
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 7.16
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell (2011) 6.23
A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell (2009) 6.20
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science (2005) 5.04
Increase in activity during calorie restriction requires Sirt1. Science (2005) 4.90
Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science (2003) 4.45
A neuronal isoform of the aplysia CPEB has prion-like properties. Cell (2003) 4.16
Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science (2004) 4.01
Prions as adaptive conduits of memory and inheritance. Nat Rev Genet (2005) 3.97
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell (2012) 3.44
Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell (2004) 3.43
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast (2007) 3.30
Cryptic variation in morphological evolution: HSP90 as a capacitor for loss of eyes in cavefish. Science (2013) 3.15
Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet (2009) 3.06
Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science (2002) 3.05
HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell (2012) 2.94
α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol (2010) 2.93
Prions are a common mechanism for phenotypic inheritance in wild yeasts. Nature (2012) 2.89
Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science (2013) 2.79
Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol (2011) 2.70
Hsp90 and environmental stress transform the adaptive value of natural genetic variation. Science (2010) 2.68
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
A natively unfolded yeast prion monomer adopts an ensemble of collapsed and rapidly fluctuating structures. Proc Natl Acad Sci U S A (2007) 2.62
Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (2013) 2.61
Prion switching in response to environmental stress. PLoS Biol (2008) 2.61
Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A (2006) 2.59
Prion recognition elements govern nucleation, strain specificity and species barriers. Nature (2007) 2.57
Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci (2005) 2.50
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A (2009) 2.35
Prions as protein-based genetic elements. Annu Rev Microbiol (2002) 2.21
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell (2006) 2.14
Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol (2011) 2.11
Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci U S A (2008) 2.09
Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell (2006) 2.09
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A (2011) 2.03
Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays (2004) 2.02
Retracted SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci (2012) 2.00
Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science (2002) 1.99
The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. Proc Natl Acad Sci U S A (2007) 1.99
Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry (2002) 1.98
Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci (2006) 1.98
A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol (2011) 1.95
Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal. Proc Natl Acad Sci U S A (2006) 1.92
Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets (2009) 1.91
Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol (2013) 1.88
Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. Annu Rev Genet (2010) 1.88
Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci U S A (2008) 1.88
HSP90 affects the expression of genetic variation and developmental stability in quantitative traits. Proc Natl Acad Sci U S A (2008) 1.87
Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science (2013) 1.85
Widespread regulation of translation by elongation pausing in heat shock. Mol Cell (2013) 1.85
A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A (2006) 1.85
Epigenetics in the extreme: prions and the inheritance of environmentally acquired traits. Science (2010) 1.84
Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. EMBO J (2008) 1.82
Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev (2008) 1.81
The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J (2011) 1.80
Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat Struct Mol Biol (2007) 1.77
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet (2006) 1.77
Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci U S A (2006) 1.76
Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A (2010) 1.73
Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol (2010) 1.63
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A (2004) 1.62